A systematic review of the burden of pertussis in South Korea

Mungall, Bruce A.; Kim, Hyungwoo; Oh, Kyu-Bin

doi:10.1080/21645515.2020.1844505

Cited by 9 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pertussis is a highly contagious respiratory infection; although universal vaccination substantially reduced the numbers of cases and deaths, epidemic cycles occur every two to five years, even in countries with high vaccination coverage. 2 5 Studies have demonstrated that the protection induced by immunization wanes rapidly, being effective for only 2–3 years. 29 Many countries recommend Tdap administration in those aged 11–12 years and a decennial booster dose of Td or Tdap.…”

Section: Discussionmentioning

confidence: 99%

“…Diphtheria, tetanus, and pertussis are community-acquired infectious diseases that can be life-threatening. 1 2 Despite the substantial decline in incidence of diphtheria and tetanus and their near elimination due to immunization in developed countries, these diseases remain endemic in some developing countries with low vaccination coverage. Outbreaks of diphtheria are reported continuously in regions that are predominantly rural or in a state of economic crisis or civil war.…”

Section: Introductionmentioning

confidence: 99%

“…4 Pertussis outbreaks, on the other hand, occur cyclically worldwide, including in developed countries with high vaccination coverage. 2 5 6 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Double-blind, Active-Controlled Phase 3 Trial

et al. 2021

View full text Add to dashboard Cite

Background Although the combination tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) is recommended at adolescence in developed countries, the tetanus and diphtheria toxoid vaccine (Td), which is less costly, is recommended instead in some parts of the world. A new Td, BR-TD-1001, was developed by a Korean manufacturer for distribution to endemic regions and for use in the initial step of novel Tdap development. Methods This phase 3, randomized, double-blind, multi-center trial, conducted in Korea, aimed to evaluate the immunogenicity and safety of BR-TD-1001. Healthy children aged 10 to 12 years were randomized 1:1 to receive either BR-TD-1001 or the control Td (Td-pur, GlaxoSmithKline). Antibodies were measured using enzyme-linked immunosorbent assay. Results A total of 218 subjects (BR-TD-1001, n = 108; control, n = 110) were enrolled and included in the safety analysis. Vaccine-mediated antibody responses were similar in both groups. We confirmed the non-inferiority of BR-TD-1001 against the control, Td; 100% of both groups achieved seroprotection against diphtheria and tetanus. Furthermore, there was no significant difference between groups in the proportion of participants who demonstrated boost responses against diphtheria and tetanus toxoids. The incidence of solicited local and systemic adverse events (AEs), unsolicited AEs, and serious AEs did not differ significantly between groups. Conclusion The BR-TD-1001 satisfied the immunological non-inferiority criterion against diphtheria and tetanus, with a clinically acceptable safety profile. Trial Registration ClinicalTrials.gov Identifier: NCT04618939

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Double-blind, Active-Controlled Phase 3 Trial

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Tdap for pregnant women and adults in contact with neonates has been recommended since 2017 [ 83 ]. A single dose of Tdap is also recommended for adults, with a booster dose every 10 years [ 84 ].…”

Section: East Asiamentioning

confidence: 99%

Bordetella pertussis in School-Age Children, Adolescents, and Adults: A Systematic Review of Epidemiology, Burden, and Mortality in Asia

Macina

Evans²

2021

Infect Dis Ther

View full text Add to dashboard Cite

Cyclic epidemics of pertussis (whooping cough) have been observed globally over the past twenty years despite high infant vaccine coverage. The resurgence of pertussis in high-income countries is partly due to waning vaccine immunity in older children and adults, as well as better surveillance and diagnostics. Moreover, in adolescents and adults, pertussis symptoms are mild and similar to common cough syndromes, meaning that it is under-diagnosed in older populations. A systematic search of MEDLINE, EMBASE, and BIOSIS was undertaken to identify studies published between 1 January 1990 and 17 June 2019, with information on pertussis epidemiology, burden of illness, and mortality in school-aged children, adolescents, and adults in Asia. Studies identified for inclusion were reviewed narratively because a statistical comparison was not possible due to the mix of methodologies used.The results showed that in East Asia, including Japan, South Korea, China, and Taiwan, pertussis is circulating in older children and adults. Diphtheria-tetanus-pertussis (DTP4) coverage is high in East Asia, yet outbreaks observed in Japan and South Korea suggest that vaccine-acquired immunity had waned in adolescents and adults. Several school outbreaks in China show that pertussis is circulating in young children, with continued circulation in adolescents and adults. There was a lack of information from Southeast/South Asian countries, although pan-Asian serosurveys showed that recent pertussis infection was common in adolescents and in adults with persistent cough. To conclude, the circulation of pertussis in Asian countries with high DTP4 coverage supports the expansion of routine vaccination to include booster doses for children at school entry and adolescents. However, surveillance is weak or absent in many countries, meaning that the true burden of pertussis, particularly among older populations, is unknown.

show abstract

“…In general, people are vulnerable to infection, but children are more susceptible. After decades of a consistently low incidence of scarlet fever and pertussis, a dramatic increase has been seen in many countries in recent years, such as the United Kingdom [ 1 , 2 ], China [ 3 , 4 ], and Korea [ 5 , 6 ]. Scarlet fever is an acute respiratory infection that develops in some people who have strep throat.…”

Section: Introductionmentioning

confidence: 99%

Collateral Impact of COVID-19 Prevention Measures on Re-Emergence of Scarlet Fever and Pertussis in Mainland China and Hong Kong China

Guo

et al. 2022

IJERPH

View full text Add to dashboard Cite

The incidence of scarlet fever and pertussis has increased significantly in China in recent years. During the COVID-19 pandemic, stringent non-pharmaceutical intervention measures were widely adopted to contain the spread of the virus, which may also have essential collateral impacts on other infectious diseases, such as scarlet fever and pertussis. We compared the incidence data of scarlet fever and pertussis in Mainland China and Hong Kong from 2004 to 2021 before and after the COVID-19 pandemic. The results show that the incidence of both diseases decreased significantly in 2020–2021 compared to the after-re-emergence stage in these two locations. Specifically, in 2020, scarlet fever decreased by 73.13% and pertussis by 76.63% in Mainland China, and 83.70% and 76.10%, respectively, in Hong Kong. In the absence of COVID-19, the predicted incidence of both diseases was much higher than the actual incidence in Mainland China and Hong Kong in 2020–2021. This study demonstrates that non-pharmaceutical measures implemented during the COVID-19 pandemic can partially reduce scarlet fever and pertussis re-emergence in Mainland China and Hong Kong.

show abstract

A systematic review of the burden of pertussis in South Korea

Cited by 9 publications

References 34 publications

Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Double-blind, Active-Controlled Phase 3 Trial

Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Double-blind, Active-Controlled Phase 3 Trial

Bordetella pertussis in School-Age Children, Adolescents, and Adults: A Systematic Review of Epidemiology, Burden, and Mortality in Asia

Collateral Impact of COVID-19 Prevention Measures on Re-Emergence of Scarlet Fever and Pertussis in Mainland China and Hong Kong China

Contact Info

Product

Resources

About